AU2021455992A1 - Il1ra derived peptides for treatment of diabetic nephropathy - Google Patents
Il1ra derived peptides for treatment of diabetic nephropathy Download PDFInfo
- Publication number
- AU2021455992A1 AU2021455992A1 AU2021455992A AU2021455992A AU2021455992A1 AU 2021455992 A1 AU2021455992 A1 AU 2021455992A1 AU 2021455992 A AU2021455992 A AU 2021455992A AU 2021455992 A AU2021455992 A AU 2021455992A AU 2021455992 A1 AU2021455992 A1 AU 2021455992A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- amino acid
- seq
- use according
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/069450 WO2023284947A1 (en) | 2021-07-13 | 2021-07-13 | Il1ra derived peptides for treatment of diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021455992A1 true AU2021455992A1 (en) | 2024-01-18 |
Family
ID=76958978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021455992A Pending AU2021455992A1 (en) | 2021-07-13 | 2021-07-13 | Il1ra derived peptides for treatment of diabetic nephropathy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240216464A1 (https=) |
| EP (1) | EP4351617B1 (https=) |
| JP (1) | JP7839260B2 (https=) |
| CN (1) | CN117642174A (https=) |
| AU (1) | AU2021455992A1 (https=) |
| CA (1) | CA3226176A1 (https=) |
| ES (1) | ES3026437T3 (https=) |
| WO (1) | WO2023284947A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| KR101317045B1 (ko) * | 2002-09-06 | 2013-10-16 | 암젠 인코포레이티드 | 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체 |
| ES2600616T3 (es) * | 2011-03-14 | 2017-02-10 | Phlogo Aps | Antagonistas del receptor de la interleucina-1 |
| WO2017063657A1 (en) * | 2015-10-14 | 2017-04-20 | Phlogo Aps | Il1ra-derived peptide antagonist |
| WO2018022982A1 (en) * | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
-
2021
- 2021-07-13 JP JP2024501194A patent/JP7839260B2/ja active Active
- 2021-07-13 WO PCT/EP2021/069450 patent/WO2023284947A1/en not_active Ceased
- 2021-07-13 AU AU2021455992A patent/AU2021455992A1/en active Pending
- 2021-07-13 CA CA3226176A patent/CA3226176A1/en active Pending
- 2021-07-13 ES ES21742823T patent/ES3026437T3/es active Active
- 2021-07-13 EP EP21742823.4A patent/EP4351617B1/en active Active
- 2021-07-13 US US18/577,588 patent/US20240216464A1/en active Pending
- 2021-07-13 CN CN202180100484.5A patent/CN117642174A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3226176A1 (en) | 2023-01-19 |
| JP7839260B2 (ja) | 2026-04-01 |
| EP4351617B1 (en) | 2025-03-26 |
| WO2023284947A1 (en) | 2023-01-19 |
| EP4351617C0 (en) | 2025-03-26 |
| JP2024525669A (ja) | 2024-07-12 |
| EP4351617A1 (en) | 2024-04-17 |
| ES3026437T3 (en) | 2025-06-11 |
| US20240216464A1 (en) | 2024-07-04 |
| CN117642174A (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Takashima et al. | Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy | |
| CN109475592B (zh) | 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物 | |
| CN1960758B (zh) | 关节炎的治疗剂或预防剂 | |
| CN101541957B (zh) | 利尿钠多肽 | |
| JP2021185178A (ja) | 胆汁酸に関係した障害の治療方法 | |
| TW200817431A (en) | Diuretic and natriuretic polypeptides | |
| JP2003535037A (ja) | 炎症を治療する方法 | |
| US20200188471A1 (en) | Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis | |
| Zhang et al. | Reversing CXCL10 deficiency ameliorates kidney disease in diabetic mice | |
| EP4351617B1 (en) | Il1ra derived peptides for treatment of diabetic nephropathy | |
| US20220288054A1 (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) | |
| EP3800196B1 (en) | Peptide for treating rheumatoid arthritis and use thereof | |
| CA3244198C (en) | Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy | |
| CN118420740A (zh) | 一类半抗原和脂肪酸双修饰的BimBH3模拟肽及其制备方法和应用 | |
| EP4422659B1 (en) | Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy | |
| JP2004008027A (ja) | ｃＡＭＰの産生活性を有する新規ペプチド | |
| WO2024011946A1 (en) | Polypeptide dimers for the treatment of systemic sclerosis | |
| WO2014188373A1 (en) | Chromogranin-a-derived polypeptides and methods of use | |
| WO2017063657A1 (en) | Il1ra-derived peptide antagonist | |
| Bonnet | Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases 2 | |
| HK40005282A (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| HK1138333A (en) | Methods of diagnosing and treating an inflammatory response |